Gregory Q. Marsella, M.D. | Curriculum Vitae 2017-05-01T17:52:45+00:00
  • March 1997- Present
    Principal Investigator: Da Vinci Research Institute
    Boca Raton, Florida
    Contract Clinical Trials and Grant-Based Medical Research
  • April 1992-Present
    Private Practice of Adult and Adolescent Psychiatry/Psychopharmacology
    Boca Raton, Florida
    Miami, Florida
  • November 2009-Present
    Neuronetics Neurostar rTMS and Brainsway rDTMS Therapy
    Chrysalis TMS Institute
    Boca Raton, Florida
    Miami, Florida
    Repetitive Transcranial Magnetic Stimulation
    Deep Repetitive Transcranial Magnetic Stimulation
  • July 1987-April 1992
    Delray Medical Center
    Delray Beach, Florida
    Director of Adolescent Psychiatric Treatment Services
    Medical Director of Adolescent Psychiatric Inpatient Unit
  • 1984-1987
    New York Hospital-Cornell Medical Center-Westchester
    Psychiatry Residency
  • 1983-1984
    New York Hospital-Cornell Medical Center-Payne Whitney;
    New York Hospital-Cornell Medical Center-Westchester;
    Memorial Sloan-Kettering Cancer Center;
    Laguardia Hospital-Forest Hills
    Internship
  • 1978-1983
    University of Pennsylvania School of Medicine
    Philadelphia, Pennsylvania
    Doctor of Medicine Degree
  • 1971-1976
    Harvard University
    Cambridge, Massachusetts
    B.A. Degree Cum Laude in English Literature;
    Thesis Rank: Magna Cum Laude
  • Medical School
    -8 week clerkship in Adult Psychiatry, Hospital of the University of Pennsylvania (HUP)
    -8 week externship in Advanced Inpatient Psychiatry, HUP
    -4 week clerkship in Child Psychiatry, Philadelphia Child Guidance Clinic, HUP
    -4 week Specialized Study in Psychiatry (Psychoanalysis), HUP
  • Internship
    -2 months Neurology, Memorial Sloan-Kettering Cancer Center
    -4 months Medicine, Laguardia Hospital-Forest Hills
    -2 months Geriatric Psychiatry, New York Hospital-Cornell Medical Center
    -2 months Drug and Alcohol Rehabilitation, New York Hospital-Cornell Medical Center
    -2 months Psychiatric Evaluation Service, New York Hospital-Cornell Medical Center
  • Psychiatry Residency
    -6 months Diagnostic Evaluation Services, New York Hospital-Cornell Medical Center
    -6 months Psychiatric Inpatient Services, New York Hospital-Cornell Medical Center
    -12 months Adult Outpatient Psychiatry, New York Hospital-Cornell Medical Center
    -3 months Child and Adolescent Psychiatry, New York Hospital-Cornell Medical Center
    -6 months Adolescent Inpatient Services, New York Hospital-Cornell Medical Center
    -3 months Consultation-Liaison Services, New York Hospital-Cornell Medical Center
  • “Nefazodone in the Treatment of Patients with Chronic Pain.” (authored by Dr. Marsella, subsidized by a grant from Bristol-Myers Squibb)
  • “A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of the Efficacy of Sertraline in the Treatment of Dysthymia.” (authored by Dr. Marsella, subsidized by a grant from Pfizer)
  • “Nefazodone in the Treatment of Agitated Geriatric Patients.” (authored by Dr. Marsella, subsidized by a grant from Bristol-Myers Squibb)
  • “A Placebo-Controlled Study of Olanzapine Monotherapy in the Treatment of Bipolar I Depression.” (sponsored by Eli Lilly)
  • “An Open-Label Combination of Olanzapine and Fluoxetine in Major Depressive Disorder.” (sponsored by Eli Lilly)
  • “A Twelve-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Posttraumatic Stress Disorder (PTSD).” (sponsored by GlaxoSmithKline)
  • “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Two Doses of Aripiprazole in the Treatment of Hospitalized Patients with Acute Mania.” (sponsored by Bristol-Myers Squibb)
  • “An Open-Label Study of Tolerability, Clinical Response, and Satisfaction in Adult Bipolar I Subjects Optimizing Initiation of Therapy Using Administration of Dermatological Precautions and Lamictal Titration Packs.” (sponsored by GlaxoSmithKline)
  • “A Multi-Center, Open-Label, Long-Term Study of the Safety, Tolerability and Efficacy of Aripiprazole in the Maintenance Treatment of Patients with Bipolar Disorders.” (sponsored by Bristol-Myers Squibb)
  • “An Open-Label Evaluation of Lamotrigine Versus Carbamapezine, Phenytoin, and Divalproex Sodium as Monotherapy Treatment for Epilepsy Patients Who Have Failed a Previous Course of Anti-Epileptic Drug Therapy.” (sponsored by GlaxoSmithKline)
  • “Open-Label Use of Keppra (Levetiracetam) in the Treatment of Agitated States in Patients Over 50.” (authored by Dr. Marsella, subsidized by a grant from UCB Pharma)
  • “Lilly’s Emotional and Physical Symptoms of Depression Study.” (sponsored by Eli Lilly)
  • “A Multicenter, Randomized, Open-Label, Parallel-Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment with Niravam and an SSRI or SNRI to Treatment with an SSRI or SNRI Alone in Subjects with Generalized Anxiety Disorder or Panic Disorder.” (sponsored by Schwarz Pharma)
  • “A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With a Diagnosis of Bipolar I Depression.” (sponsored by Pfizer)
  • “An International, Multicenter, Large Simple Trial (LST) to Compare the Cardiovascular Safety of Ziprasidone and Olanzapine in Patients With Schizophrenia.” (sponsored by Pfizer)
  • “A Multicenter, Double-Blind Study on the Efficacy and Safety of Aripiprazole in Combination with Lamotrigine in the Long-Term Maintenance Treatment of Patients with Bipolar I Disorder with a Recent Manic or Mixed Episode.” (sponsored by Bristol-Myers Squibb)
  • “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder.” (sponsored by Bristol-Myers Squibb)
  • “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study with Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents with Autistic Disorder.” (sponsored by Bristol-Myers Squibb)
  • “A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder.” (sponsored by Bristol-Myers Squibb)
  • “A Randomized, Multi-Center, Double-Blind, Parallel-Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenia Patients.” (sponsored by Solvay Pharmaceuticals)
  • “A Multi-Center, Open-Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder.” (sponsored by Solvay Pharmaceuticals)
  • “Risperidone in the Treatment of Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety Followed by an Open-Label Extension Study of Safety.” (sponsored by Johnson & Johnson)
  • “A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of AVE1625 5, 10, and 30 mg and Placebo on top of an Established Treatment Regimen of Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole Monotherapy in the Treatment of Cognitive Impairment in Schizophrenia.” (sponsored by Sanofi-Aventis)
  • “Best Estimate Diagnosis Used to Evaluate EEG in Association With ADHD in a Multi-Site, Clinical Sample of Children and Adolescents.” (sponsored by Lexicor Medical Technology)
  • “A Phase Two, Six-Week, Double-Blind, Placebo-Controlled, Multicenter Trial of Varenicline Tartrate (CP-526,555) for Cognitive Impairment in Subjects with Schizophrenia.” (sponsored by Pfizer)
  • “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain.” (sponsored by Wyeth)
  • “A Multicenter, Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain.” (sponsored by Wyeth)
  • “An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Extended-release in Children and Adolescent Subjects with Bipolar Depression.” (sponsored by AstraZeneca)
  • “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study (804P301) to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Two Concomitant Antiepileptic Medications.” (sponsored by Supernus)
  • “A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Two Concomitant Antiepileptic Medications.” (sponsored by Supernus)
  • “A Six-Month, Multi-Center, Placebo-Controlled, Chronic Migraine Treatment Trial with combination Topamax (50-100mg) and either Propranolol or Placebo.” (sponsored by the NIH: National Institute of Neurological Disorders and Stroke/National Institutes of Health)
  • “NeuroStar TMS Therapy System: Data Management, Analysis and Reporting Format for Clinical Treatment Utilization and Outcomes.” (sponsored by Neuronetics)
  • “A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder.” (sponsored by Forrest Pharmaceuticals)
  • “A Long Term, Open Label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder.” (sponsored by Forrest Pharmaceuticals)
  • “A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant treatment.” (sponsored by Astra Zeneca)
  • “A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor treatment.” (sponsored by Eli Lilly)
  • “A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute treatment of Adults With Major Depressive Disorder.” (sponsored by Takeda)
  • “A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder.” (sponsored by Takeda)
  • A Phase 3, Multi-center, Four Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)(Sponsored by Pfizer | CRO ICON)
  • A Phase 3, Multi-center, Four Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)(Sponsored by Pfizer | CRO ICON)
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Male Subjects with Autism Spectrum Disorder.
  • [/fusion_checklist] [/fusion_tab][/fusion_tabs]